News for Arcutis Biotherapeutics, Inc. (ARQT)

Summary Arcutis Biotherapeutics Inc (ARQT), a commercial-stage biopharmaceutical company specializing in immuno-dermatology, announced on May 29, 2025, that it

WESTLAKE VILLAGE, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. ( ARQT), a commercial-stage biopharmaceutical company focused on deve

On May 23, 2025, analyst Serge Belanger from Needham provided an updated analysis on Arcutis Biotherapeutics (ARQT), reiterating a 'Buy' rating for the stock. T

Summary Arcutis Biotherapeutics Inc (ARQT), a commercial-stage biopharmaceutical company, has announced the FDA approval of its supplemental New Drug Applicatio

Once-daily ZORYVE foam provides powerful clearance and rapid itch relief from head to toe with no limitation on duration of useMore than half of the nearly 9 mi

Quick Summary: Arcutis Biotherapeutics secures fifth FDA approval for Zoryve within three years. Analysts predict a potential 55.12% upside in the stock

Arcutis Biotherapeutics (ARQT) has secured approval from the U.S. Food and Drug Administration for its supplemental New Drug Application for Zoryve topical foam

Arcutis Biotherapeutics (ARQT) has announced the release of 14 consensus statements from the Genital Psoriasis Wellness Consortium, now published in the Journal

Arcutis Biotherapeutics (ARQT) publishes 14 consensus statements on genital psoriasis in JEADV Clinical Practice. Statements aim to improve diagnosis, t

Revenue: $63.8 million in Q1 2025, up 196% year-over-year.Net Product Revenue for ZORYVE: $68.3 million, reflecting a 196% growth year-over-year.Prescription D

Robust product revenue growth with ZORYVE cream and foam driving increased market demand.Strategic commercialization and licensing agreements bolstering revenu

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ETCompany ParticipantsAmanda Sheldon - Head of Corporate...

Summary Arcutis Biotherapeutics Inc (ARQT), a commercial-stage biopharmaceutical company specializing in immuno-dermatology, announced on April 17, 2025, that i

WESTLAKE VILLAGE, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. ( ARQT), a commercial-stage biopharmaceutical company focused on de

Summary Arcutis Biotherapeutics Inc (ARQT), a commercial-stage biopharmaceutical company specializing in immuno-dermatology, announced on April 10, 2025, that i

Arcutis Biotherapeutics, Inc. (ARQT) revealed a leadership change with the upcoming retirement of its Chief Financial Officer, David Topper. In a planned succes

WESTLAKE VILLAGE, Calif., April 10, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. ( ARQT), a commercial-stage biopharmaceutical company focused on de

Arcutis Biotherapeutics (ARQT) announces CFO transition with David Topper retiring and Latha Vairavan stepping in. Transition effective post Q1 10-Q fil

**media[592048,592049]**